Issue and repurchase of class C shares for incentive program
By virtue of authorization by the general meeting on 21 November 2016, the board of directors of Hansa Medical AB (publ) has resolved to issue and immediately thereafter repurchase 401,000 class C shares.
The shares are issued and repurchased in accordance with the performance based incentive programme, LTIP 2016, which was adopted by the extraordinary general meeting held on 21 November 2016.
Carnegie Investment Bank AB (publ) will subscribe for the entire issue of new class C shares at a subscription price of SEK 1 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the board of directors’ resolution, be repurchased by Hansa Medical for the same price. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2016.
The purpose of the repurchase is to ensure delivery of performance shares under LTIP 2016 and to secure possible social charges arising as a result of LTIP 2016. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right. Hansa Medical has previously not issued any class C shares.
The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CEST on 27 April
2017.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB (publ)
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late- stage clinical development for kidney transplant patients,
with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.
Tags: